Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:TERN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeTERNTerns Pharmaceuticals$3.02-0.7%$2.89$1.87▼$11.40$263.76M-0.161.53 million shs841,210 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceTERNTerns Pharmaceuticals0.00%-13.14%+42.06%-31.84%-45.32%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationTERNTerns Pharmaceuticals4.3741 of 5 stars3.32.00.04.14.03.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceTERNTerns Pharmaceuticals 2.60Moderate Buy$18.38508.44% UpsideCurrent Analyst Ratings BreakdownLatest TERN, GV2O, PU11, and JPB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2025TERNTerns PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$20.00 ➝ $20.003/21/2025TERNTerns PharmaceuticalsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform2/28/2025TERNTerns PharmaceuticalsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Perform(Data available from 5/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookTERNTerns PharmaceuticalsN/AN/AN/AN/A$4.13 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateTERNTerns Pharmaceuticals-$90.21M-$1.09N/AN/AN/AN/A-32.76%-31.33%5/12/2025 (Estimated)Latest TERN, GV2O, PU11, and JPB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025TERNTerns Pharmaceuticals-$0.29-$0.26+$0.03-$0.26N/AN/A3/20/2025Q4 2024TERNTerns Pharmaceuticals-$0.30-$0.24+$0.06-$0.24N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthTERNTerns PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioTERNTerns PharmaceuticalsN/A32.9932.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipTERNTerns Pharmaceuticals98.26%Insider OwnershipCompanyInsider OwnershipTERNTerns Pharmaceuticals15.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableTERNTerns Pharmaceuticals4087.34 million72.11 millionNot OptionableTERN, GV2O, PU11, and JPB HeadlinesRecent News About These CompaniesDriehaus Capital Management LLC Decreases Stock Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)May 12 at 5:26 AM | marketbeat.comWhy Terns Pharmaceuticals, Inc.’s (TERN) Stock Is Up 11.67%May 10 at 4:11 AM | aaii.comIs Terns Pharmaceuticals, Inc. (TERN) the Low Risk High Reward Stock Set to Triple by 2030?May 9 at 7:56 AM | insidermonkey.comTerns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate UpdatesMay 8, 2025 | globenewswire.comTerns Pharmaceuticals (TERN) to Post Earnings on MondayMay 7, 2025 | marketbeat.comJPMorgan Chase & Co. Reduces Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)May 5, 2025 | marketbeat.comAcorn Capital Advisors LLC Invests $10.92 Million in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)May 4, 2025 | marketbeat.comBoxer Capital Management LLC Takes $4.17 Million Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)May 4, 2025 | marketbeat.comTerns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)May 2, 2025 | globenewswire.comWhy Terns Pharmaceuticals, Inc.’s (TERN) Stock Is Up 5.15%May 2, 2025 | aaii.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Shares Acquired by Schonfeld Strategic Advisors LLCMay 1, 2025 | marketbeat.comTerns Pharmaceuticals to Participate in The Citizens Life Sciences ConferenceApril 30, 2025 | globenewswire.comBarclays PLC Purchases 575,069 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN)April 29, 2025 | marketbeat.comMarshall Wace LLP Grows Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)April 27, 2025 | marketbeat.comGeode Capital Management LLC Has $8.40 Million Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)April 26, 2025 | marketbeat.comRenaissance Technologies LLC Grows Stock Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)April 25, 2025 | marketbeat.comTerns Pharmaceuticals (NASDAQ:TERN) Given Market Outperform Rating at JMP SecuritiesApril 23, 2025 | marketbeat.comDoes Terns Pharmaceuticals Have A Long Cash Runway?April 23, 2025 | finance.yahoo.comWhy Terns Pharmaceuticals, Inc.’s (TERN) Stock Is Up 5.83%April 21, 2025 | aaii.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Shares Bought by Altium Capital Management LLCApril 20, 2025 | marketbeat.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Stock Position Raised by LPL Financial LLCApril 20, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesS&P 500 and Nasdaq-100 Flashed Death Crosses—Should You Worry?By Jea Yu | April 23, 2025View S&P 500 and Nasdaq-100 Flashed Death Crosses—Should You Worry?2 Penny Stocks With $10 Potential By Thomas Hughes | April 16, 2025View 2 Penny Stocks With $10 Potential Western Digital: Is the Storage Sector Set for a Rebound?By Jeffrey Neal Johnson | May 4, 2025View Western Digital: Is the Storage Sector Set for a Rebound?Is It Time to Load Up on Bond ETFs?By Nathan Reiff | May 2, 2025View Is It Time to Load Up on Bond ETFs?3 Stocks Lifting 2025 Guidance Despite Market JittersBy Leo Miller | April 29, 2025View 3 Stocks Lifting 2025 Guidance Despite Market JittersTERN, GV2O, PU11, and JPB Company DescriptionsTerns Pharmaceuticals NASDAQ:TERN$3.02 -0.02 (-0.66%) Closing price 04:00 PM EasternExtended Trading$2.99 -0.03 (-0.96%) As of 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
